STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the	1
		title or the abstract	
		(b) Provide in the abstract an informative and balanced summary of	4
		what was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation	6
		being reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	8
Setting	5	Describe the setting, locations, and relevant dates, including periods	8
		of recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of	8
		selection of participants	
Variables	7	Clearly define all outcomes, exposures, predictors, potential	8
		confounders, and effect modifiers. Give diagnostic criteria, if	
		applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of	8 and 9
measurement		methods of assessment (measurement). Describe comparability of	
		assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	9 and 10
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If	9
		applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control	9 and 10
		for confounding	
		(b) Describe any methods used to examine subgroups and	10 and 10
		interactions	
		(c) Explain how missing data were addressed	10
		(d) If applicable, describe analytical methods taking account of	Not
		sampling strategy	applicable
		(e) Describe any sensitivity analyses	Not
			applicable
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg	12
		numbers potentially eligible, examined for eligibility, confirmed	
		eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	12
		(c) Consider use of a flow diagram	Not
			applicable
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic,	12
		clinical, social) and information on exposures and potential	
		confounders	

	(h) Indicate number of participants with missing data for each	12
	• • •	12
15*		12
16	· · · · · · · · · · · · · · · · · · ·	12 and 13
	11	
	Make clear which confounders were adjusted for and why they were	
	included	
	(b) Report category boundaries when continuous variables were	12
	categorized	
	(c) If relevant, consider translating estimates of relative risk into	12
	absolute risk for a meaningful time period	
17	Report other analyses done—eg analyses of subgroups and	12 an d13
	interactions, and sensitivity analyses	
18	Summarise key results with reference to study objectives	14
19	Discuss limitations of the study, taking into account sources of	16
	potential bias or imprecision. Discuss both direction and magnitude	
	of any potential bias	
20	Give a cautious overall interpretation of results considering	14 and 15
	objectives, limitations, multiplicity of analyses, results from similar	
	studies, and other relevant evidence	
21	Discuss the generalisability (external validity) of the study results	15 and 16
22	Give the source of funding and the role of the funders for the present	18
	study and, if applicable, for the original study on which the present	
	article is based	
	17 18 19 20 21	16 (a) Give unadjusted estimates and, if applicable, confounderadjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses 18 Summarise key results with reference to study objectives 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence 21 Discuss the generalisability (external validity) of the study results 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present

^{*}Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.